Advance Multitech Ltd has successfully allotted 97,25,000 fully convertible warrants to 118 non-promoter allottees at Rs 40 per warrant. The company has secured Rs 9.725 crore as the mandatory 25% upfront payment. These warrants are convertible into equity shares within 18 months, representing a total potential capital infusion of Rs 38.9 crore for the company.
Advance Multitech Completes Rs 38.9 Crore Warrant Allotment
Allotment: 97,25,000 warrants at Rs 40 each.
Upfront Payment: Rs 9.725 crore received (25% of total).
Reader Takeaway: Immediate cash boost for business expansion against future equity dilution risks for existing retail shareholders.
What just happened
Advance Multitech Ltd has officially completed the allotment of 97,25,000 fully convertible warrants to 118 non-promoter allottees. Each warrant was issued at a price of Rs 40, which includes a Rs 30 premium over the face value of Rs 10. The company has successfully collected the mandatory 25% upfront subscription amount, totaling Rs 9.725 crore.
Why this matters
This transaction serves as a capital-raising mechanism. By securing these funds, the company bolsters its immediate liquidity position. The remaining 75% of the total issue value, amounting to Rs 29.175 crore, will be received when the warrant holders exercise their right to convert these instruments into equity shares. This creates a staggered inflow of capital tied to the company's future performance.
The conversion process
The warrants grant holders the right to apply for fully paid-up equity shares at any time within 18 months from the date of allotment. The conversion is subject to the payment of the remaining balance. Once converted, these warrants will rank pari passu with the existing equity shares of the company.
Governance and approvals
The issuance adheres to regulatory standards, having received board approval on September 1, 2026, and shareholder endorsement during the Annual General Meeting on September 28, 2026. The company also secured in-principle approval from the BSE on October 12, 2026, ensuring compliance with stock exchange norms.
Risks to watch
While the infusion of capital is a positive development, existing shareholders should remain mindful of future equity dilution. Upon conversion, the company's equity base will expand, which could impact the Earnings Per Share (EPS) for current investors if the capital deployed does not generate proportional growth in net profits within the expected timeline.
